List of Excipients in Branded Drug IDOSE TR

« Back to Dashboard

iDose TR Excipient Strategy and Commercial Opportunities in Sustained-Release Glaucoma Therapy

Last updated: September 28, 2026

iDose TR is a preservative-free, intracameral travoprost delivery system developed by Glaukos Corporation for reduction of elevated intraocular pressure in adults with primary open-angle glaucoma or ocular hypertension. Its commercial differentiation comes from controlled drug release through a titanium implant rather than from a conventional ophthalmic excipient system. The formulation strategy minimizes exposure to preservatives and topical formulation tolerability issues, while the commercial model shifts treatment from daily patient administration to a physician-administered procedure followed by sustained drug delivery.

What is iDose TR and how does its formulation work?

iDose TR is a drug-device combination product containing travoprost, a prostaglandin analog, in a small intracameral implant. The implant is placed through an ab interno procedure and positioned in the trabecular region of the eye. The drug is released over time through a controlled-delivery mechanism. The FDA approved iDose TR in December 2023 for reduction of elevated intraocular pressure in patients with primary open-angle glaucoma or ocular hypertension.[1]

The key formulation characteristics are:

Attribute	iDose TR profile
Active pharmaceutical ingredient	Travoprost
Dosage form	Intracameral implant
Route of administration	Physician-administered intraocular placement
Preservative status	Preservative-free delivery system
Device material	Titanium-based implant structure
Drug release	Controlled, sustained intraocular release
FDA product category	Drug-device combination product
Indication	Reduction of elevated intraocular pressure
Primary commercial alternative	Daily topical prostaglandin analog therapy
Primary procedural comparator	Other intraocular drug-delivery implants

Unlike a conventional eye drop, iDose TR does not require a vehicle such as purified water, buffer, surfactant, viscosity modifier, solubilizer, or preservative to maintain a liquid formulation during repeated topical administration. The implant itself controls drug exposure.

Does iDose TR contain conventional pharmaceutical excipients?

Public FDA labeling describes iDose TR as a travoprost-containing implant and identifies the titanium implant and delivery components. The product’s principal formulation strategy is based on the drug reservoir, implant materials, and release-control architecture rather than on a conventional excipient package.[1]

For regulatory and patent purposes, the relevant formulation components include:

• Travoprost drug substance
• Implant reservoir and structural materials
• Drug-retention and release-control elements
• Delivery-system components
• Packaging and sterilization controls

The absence of a conventional topical excipient system is commercially important. It reduces the need to manage preservative-related ocular-surface concerns associated with chronic eye-drop use, particularly benzalkonium chloride exposure. It also limits opportunities for competitors to design around iDose TR through routine changes in buffer, tonicity agent, or viscosity modifier.

What excipient strategy does iDose TR use?

The iDose TR strategy is better characterized as an excipient-minimization strategy than as a traditional excipient-selection strategy.

Controlled delivery replaces liquid formulation optimization

Topical travoprost products must maintain drug solubility, physical stability, sterility, drop uniformity, ocular residence time, and tolerability. Those requirements often drive the use of surfactants, solubilizers, oils, buffers, and preservatives.

iDose TR moves those functions into the device. The delivery system determines:

• The quantity of travoprost loaded into the implant
• The exposed surface area
• The release pathway
• The rate of diffusion or elution
• The duration of intraocular exposure
• The local concentration profile

This approach reduces reliance on excipients but increases dependence on device engineering, implant placement, sterilization, and manufacturing precision.

Why preservative-free delivery matters

Chronic topical glaucoma therapy is associated with adherence problems and ocular-surface exposure to preservatives. A preservative-free implant can support a differentiated clinical and commercial position, particularly for patients with:

• Ocular-surface disease
• Multiple topical medications
• Poor drop administration technique
• Poor medication adherence
• Intolerance to preserved ophthalmic products
• Limited dexterity or visual impairment

The preservative-free profile does not eliminate all ocular risks. FDA labeling includes warnings and precautions relating to corneal endothelial cell loss, corneal edema, iritis, macular edema, hypotony, and other procedural or ocular complications.[1]

The formulation burden shifts to combination-product controls

The lack of conventional excipients does not make development simple. It shifts technical risk into:

• Drug-device compatibility
• Travoprost stability in the implant
• Extractables and leachables
• Titanium and coating biocompatibility
• Sterility assurance
• Particulate control
• Implant retention
• Dose uniformity between units
• Release-rate reproducibility
• Shelf-life stability
• Delivery-device performance

These attributes can create stronger manufacturing barriers than a conventional eye-drop formulation. A competing product may be able to match the active ingredient but still face difficulty reproducing the implant’s release profile and procedural performance.

What commercial opportunities does iDose TR create?

iDose TR creates commercial opportunities in four principal areas: adherence-sensitive glaucoma treatment, procedure-based drug delivery, preservative-free care, and lifecycle expansion.

Adherence-sensitive patient segments

Daily topical therapy remains effective when patients use it correctly. In practice, adherence can be limited by dosing frequency, forgetfulness, poor dexterity, difficulty aiming drops, and adverse ocular-surface effects.

iDose TR gives physicians a way to replace repeated patient-administered dosing with a single intervention that provides sustained exposure. The strongest commercial opportunity is likely among patients who:

• Remain uncontrolled on topical treatment
• Require multiple glaucoma medications
• Have documented adherence difficulties
• Have ocular-surface intolerance
• Are already undergoing an intraocular procedure
• Prefer fewer daily treatment steps

The product is not a universal replacement for topical therapy. It requires an intraocular procedure and carries procedural risks. Its value proposition is strongest where adherence or tolerability reduces the real-world effectiveness of eye drops.

Physician-administered revenue model

The economic model differs from a retail prescription. Commercial value may be distributed among:

• Product reimbursement
• Physician administration
• Facility reimbursement
• Follow-up care
• Reduced reliance on chronic topical prescriptions
• Improved treatment persistence

The reimbursement environment will influence adoption more than the ingredient cost. An implant can command a higher per-treatment price than generic travoprost, but physicians and facilities must receive adequate compensation for the procedure and associated monitoring.

Preservative-free positioning

Preservative-free delivery provides a marketing and clinical differentiation point against generic latanoprost, bimatoprost, travoprost, and other topical glaucoma products. The positioning is strongest for patients exposed to several preserved products over long treatment periods.

The commercial message should focus on sustained intraocular delivery and reduced daily administration burden. A claim that the implant eliminates all ocular-surface complications would be inconsistent with the FDA safety information.

How does iDose TR compare with topical prostaglandin analogs?

Factor	iDose TR	Generic topical prostaglandins
Active ingredient	Travoprost	Latanoprost, bimatoprost, travoprost and others
Administration	Physician-administered implant procedure	Patient-administered eye drop
Dosing burden	Sustained delivery	Usually daily administration
Preservatives	Preservative-free implant approach	Depends on product
Acquisition cost	Higher intervention-based cost	Low-cost recurring prescription
Adherence risk	Reduced daily dosing burden	Patient-dependent
Procedural risk	Present	Generally absent
Reversibility	Implant may require management if complications occur	Drop can be stopped or changed
Manufacturing barrier	Device, drug, sterilization, release profile	Conventional sterile ophthalmic manufacturing
Substitution risk	Generic eye drops remain a lower-cost alternative	Limited device-based differentiation

The main competitive challenge is not only another sustained-release implant. It is the low price and familiarity of generic topical therapy.

What is the FDA regulatory status of iDose TR?

The FDA approved iDose TR in December 2023. It is indicated for reduction of elevated intraocular pressure in patients with primary open-angle glaucoma or ocular hypertension.[1]

The regulatory pathway creates several commercial implications:

1. The product has established FDA approval for its active ingredient and delivery system.
2. Future modifications may require combination-product regulatory analysis.
3. Manufacturing changes affecting release kinetics, implant materials, or sterilization may have regulatory significance.
4. A follow-on product would need to address both pharmaceutical performance and device performance.
5. Regulatory exclusivity and patent protection must be analyzed separately.

FDA approval does not itself establish freedom from patent infringement. It also does not prevent an abbreviated new drug application, 505(b)(2) application, or other regulatory pathway where legally available.

What patents protect iDose TR and its delivery system?

The strongest potential protection is expected to arise from claims directed to the combination of:

• Travoprost in an intracameral implant
• A titanium or metal drug reservoir
• Controlled release of travoprost into the anterior chamber
• Implant geometry and positioning
• Release apertures or diffusion pathways
• Delivery through an ab interno procedure
• Sterile packaging and implantation systems
• Treatment of elevated intraocular pressure using the implant

Why device and formulation claims matter

A conventional composition claim covering travoprost would have limited value because travoprost is an established active ingredient. The commercially important claims are more likely to reside in the delivery architecture and the specific combination of drug, implant, placement site, and release characteristics.

Potentially valuable claim categories include:

Claim category	Commercial relevance
Composition of matter	Likely limited for established travoprost
Drug-device combination	High relevance to iDose TR
Implant structure	May block close mechanical copies
Release profile	Can protect the clinical performance of the product
Implant placement	May cover procedural use
Method of treatment	Supports indication-specific enforcement
Manufacturing process	Can create scale-up and process barriers
Sterilization and packaging	Supports quality and shelf-life protection

Patent strength depends on claim breadth, priority dates, prosecution history, terminal disclaimers, written-description support, and validity under obviousness and enablement standards. A patent family covering only a narrow implant geometry may be less durable than a portfolio combining drug-device claims, release characteristics, implantation methods, and manufacturing processes.

When does iDose TR lose exclusivity?

No single date determines commercial loss of exclusivity for iDose TR. The relevant dates include:

• FDA regulatory exclusivity expiration
• Orange Book-listed patent expiration
• Unlisted device or formulation patent expiration
• Pediatric exclusivity, if granted
• Patent-term adjustment
• Patent-term extension
• Litigation settlements
• Regulatory approval timing for a challenger

A device-based product may have meaningful protection outside conventional Orange Book listings. The FDA Orange Book generally lists patents submitted by an NDA applicant that claim the drug substance, drug product, or approved method of use. Certain implant, delivery-system, or manufacturing claims may not appear in the same manner as conventional formulation patents.

Orange Book status

The Orange Book should be reviewed for:

• iDose TR NDA listings
• Drug product patents
• Method-of-use patents
• Patent expiration dates
• Certifications required for abbreviated applications
• Any later-listed patents

Because iDose TR is a combination product, the Orange Book may not capture every commercially relevant right associated with the implant or delivery system. A complete freedom-to-operate analysis requires review of USPTO records, patent family members, international filings, and assignment records in addition to the Orange Book.[2]

Are Paragraph IV challenges likely for iDose TR?

Paragraph IV risk is possible but structurally more complex than for a conventional generic eye drop.

A challenger would need to evaluate:

• Whether an ANDA is available for the implant product
• Whether the product is better suited to a 505(b)(2) pathway
• Whether the challenger can demonstrate equivalent performance
• Whether the implant is a drug product, device, or combination for the relevant pathway
• Whether the proposed product has the same active ingredient, route, dosage form, strength, and release characteristics
• Whether listed patents cover the drug, delivery system, or approved use

Potential certification positions could include:

• The patent is invalid
• The patent is not infringed
• The patent is unenforceable
• The proposed product does not require the claimed feature
• The patent does not qualify for listing
• The challenger will wait until expiration

A Paragraph IV filing could trigger patent litigation and a potential 30-month stay under the Hatch-Waxman framework if the statutory requirements are met.[3] The timing and availability of that stay may differ if the principal dispute concerns a device component or a non-Orange-Book-listed patent.

What generic entry risks exist for iDose TR?

Generic topical prostaglandins create price pressure but do not directly replicate the iDose TR product. The more material long-term risk would come from:

1. A competing sustained-release travoprost implant.
2. A 505(b)(2) product using a different intracameral delivery system.
3. A competing implant using bimatoprost, latanoprost, or another prostaglandin analog.
4. A preservative-free injectable or implantable glaucoma therapy.
5. A procedure-linked drug-delivery platform from a major ophthalmic company.

The competitive threat is therefore platform-based. A rival does not necessarily need to copy travoprost or the iDose TR structure if it can demonstrate comparable pressure reduction with a different active ingredient and delivery system.

What manufacturing and IP barriers protect the product?

The main barriers are likely to include:

• Precision fabrication of the implant
• Drug loading consistency
• Controlled release over the intended treatment period
• Sterile manufacturing
• Low particulate burden
• Implant insertion reliability
• Device retention
• Compatibility between travoprost and implant materials
• Stability under storage conditions
• Validated release testing
• Clinical evidence for long-term safety

The release profile is particularly important. A product that releases too quickly may produce inadequate duration or excessive local exposure. A product that releases too slowly may fail to provide effective pressure reduction. Manufacturing know-how, process controls, and analytical methods can therefore supplement formal patent rights.

How strong is the iDose TR patent estate?

The estate is strategically stronger if it contains layered protection across the drug-device combination, implant architecture, release characteristics, implantation method, and manufacturing process. It is weaker if protection depends mainly on narrow structural claims or claims that can be avoided through a different reservoir, material, placement site, or release mechanism.

The likely strength profile is:

Protection layer	Relative strategic value
Travoprost composition claims	Low, because the active ingredient is established
Intracameral travoprost implant claims	High
Specific implant structure	High but potentially design-around sensitive
Controlled-release claims	High if technically specific and clinically supported
Method-of-use claims	Moderate to high
Manufacturing claims	Moderate and valuable for process control
Device-only claims	Important for competitive blocking
Trade secrets and know-how	Important for manufacturing execution

A serious competitor would need to map both issued claims and pending applications. Patent expiration dates alone do not determine entry risk because later-filed continuation patents may provide additional claims directed to revised device structures or manufacturing processes.

Which licensing opportunities exist around iDose TR?

The most credible licensing opportunities are adjacent to the core product rather than simple excipient substitution.

Potential opportunities include:

• Alternative prostaglandin analog payloads
• Combination implants for glaucoma patients requiring multiple mechanisms
• Drug-device platforms for posterior-segment disease
• Preservative-free anterior-segment delivery systems
• Implant materials and coatings
• Sterilization and packaging technologies
• Implant insertion tools
• Long-acting therapies for patients unable to self-administer drops
• Regional commercialization partnerships
• Contract manufacturing for precision implants

An excipient supplier has limited direct opportunity if the product does not depend on a conventional liquid formulation. The stronger opportunity is to supply implant-compatible materials, coatings, stabilizing matrices, drug-loading technologies, or analytical methods that support release control and combination-product manufacturing.

Key Takeaways

• iDose TR uses a preservative-free intracameral implant rather than a conventional excipient-rich ophthalmic solution.
• Its commercial differentiation is sustained travoprost delivery, reduced daily dosing, and physician-administered treatment.
• The main formulation risks involve drug-device compatibility, release-rate control, sterility, stability, and implant performance.
• Generic topical prostaglandins remain the principal price competitor.
• Direct generic substitution may be more difficult than for a standard eye drop because the product combines drug, implant, delivery procedure, and manufacturing controls.
• The most valuable intellectual property is likely to cover the drug-device combination, release profile, implant architecture, implantation method, and manufacturing process.
• Excipient suppliers have greater opportunity in implant materials, coatings, matrices, drug-loading systems, and analytical controls than in conventional buffers or preservatives.
• Future competitive risk is likely to come from alternative sustained-release glaucoma platforms, not only from travoprost copies.
• Orange Book review is necessary but may not capture every device and manufacturing right relevant to the commercial product.

FAQs

Is iDose TR preservative-free?

Yes. iDose TR is designed as a preservative-free intracameral travoprost delivery system. It avoids repeated exposure to preservatives used in some chronic topical eye-drop formulations.

Does iDose TR use benzalkonium chloride?

iDose TR is not a conventional topical ophthalmic solution and is not administered as a benzalkonium-chloride-preserved eye drop. Its delivery system is based on an intracameral implant.

Can a generic manufacturer copy the travoprost in iDose TR?

Copying the active ingredient alone would not reproduce the product. A challenger would also need to address the implant, release profile, route of administration, device performance, regulatory pathway, and applicable patents.

Is iDose TR a biologic and does it face biosimilar risk?

No. iDose TR contains travoprost, a small-molecule active ingredient, and is not a biologic. It faces generic, 505(b)(2), and competing drug-device risks rather than biosimilar substitution.

What is the largest commercial risk to iDose TR?

The largest risk is adoption economics. Low-cost generic eye drops are widely available, while iDose TR requires an intraocular procedure, reimbursement support, physician training, and acceptance of implant-related safety monitoring.

References

1. U.S. Food and Drug Administration. (2023). iDose TR prescribing information. Glaukos Corporation.

2. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations. FDA Center for Drug Evaluation and Research.

3. U.S. Food and Drug Administration. (2024). Abbreviated new drug application submissions: Refuse-to-receive standards. FDA Center for Drug Evaluation and Research.

4. Glaukos Corporation. (2024). Annual report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934. U.S. Securities and Exchange Commission.